High-Dose Mannose-Binding Lectin Therapy for Ebola Virus Infection
View/ Open
Author
Michelow, Ian C.
Lear, Calli
Scully, Corinne
Prugar, Laura I.
Longley, Clifford B.
Yantosca, L. Michael
Ji, Xin
Karpel, Marshall
Brudner, Matthew
Spear, Gregory T.
Ezekowitz, R. Alan B.
Schmidt, Emmett V.
Olinger, Gene G.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1093/infdis/jiq025Metadata
Show full item recordCitation
Michelow, Ian C., Calli Lear, Corinne Scully, Laura I. Prugar, Clifford B. Longley, L. Michael Yantosca, Xin Ji, et al. 2010. High-dose mannose-binding lectin therapy for ebola virus infection. Journal of Infectious Diseases 203(2): 175-179.Abstract
Mannose-binding lectin (MBL) targets diverse microorganisms for phagocytosis and complement-mediated lysis by binding specific surface glycans. Although recombinant human MBL (rhMBL) trials have focused on reconstitution therapy, safety studies have identified no barriers to its use at higher levels. Ebola viruses cause fatal hemorrhagic fevers for which no treatment exists and that are feared as potential biothreat agents. We found that mice whose rhMBL serum concentrations were increased ≥7-fold above average human levels survived otherwise fatal Ebola virus infections and became immune to virus rechallenge. Because Ebola glycoproteins potentially model other glycosylated viruses, rhMBL may offer a novel broad-spectrum antiviral approach.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071052/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:8646758
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)